source
- Pfizer deals extend patent life for a top-selling rare disease drugSettlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have implications for others, including BridgeBio Pharma and Alnylam.BioPharma Dive · 3mo ago↗ source
- Boehringer dual-acting obesity shot hits mark in Phase 3 trialSurvodutide spurred weight loss Wall Street analysts referred to as “Wegovy-like,” and showed signs it might help preserve muscle mass as well.BioPharma Dive · 3mo ago↗ source
- Rocket's PRV goes for $180M; Oruka targets $500M offeringRocket sells PRV for $180M: The New Jersey gene therapy maker sold the rare pediatric disease priority review voucher to an undisclosed buyer. Rocket Pharmaceuticals got the PRV after securing FDA ...